46 results
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
improvement. The CONTACT-02 trial compared the combination therapy of CABOMETYX and atezolizumab, an anti-PD-L1 (Programmed Death-Ligand 1) humanized
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
6 Jul 23
Current report (foreign)
6:18am
to serious complications including death.7 There are approximately 20,000 to 25,000 deaths globally, mainly among children, due to the virus.8 Hospital
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
23 Jun 23
Current report (foreign)
6:13am
in the risk of death (hazard ratio [HR] 0.59; 95% confidence interval [CI]: 0.396 to 0.879), with an estimated OS rate (95% CI) of 93.9% (91.6, 95.5) at 6 years
6-K
TAK
Takeda Pharmaceutical Co
9 Jun 23
Current report (foreign)
6:03am
awards and PSU awards, upon the occurrence of certain events, including the employee’s death, instead of Company ADSs, cash in an amount equivalent
6-K
EX-99.1
b0r5jomsasldwanif
30 May 23
Current report (foreign)
6:11am
6-K
b4osqx4t6aq
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
71g5i6
30 Nov 22
Current report (foreign)
6:28am
6-K
r9h0kyhe
4 Nov 22
Current report (foreign)
6:01am
6-K
8ntuht4dz 3zs
14 Oct 22
Current report (foreign)
7:36am
6-K
EX-99.1
nv79pc cqrtnknf
23 Aug 22
Current report (foreign)
6:13am
6-K
po0hte54a8dwdp2f
4 Aug 22
Current report (foreign)
6:07am
S-8
EX-99.1
psf6juupta0bw2 gna
29 Jun 22
Registration of securities for employees
6:13am
6-K
dv5ct4a
10 Jun 22
Current report (foreign)
6:00am
6-K
EX-99.1
v5qfho6 iw
31 May 22
Current report (foreign)
6:07am
6-K
vexi7s7sj
10 Feb 22
Current report (foreign)
6:03am
6-K
wpltteat
5 Nov 21
Current report (foreign)
6:02am
6-K
drm7lnq5
7 Sep 21
Current report (foreign)
6:02am
6-K
d3bgm
8 Jul 21
Current report (foreign)
6:21am